The secondary analysis of the TRIUMPH study, recently published in JAMA Cardiology, is likely the first published assessment of time spent in the target blood pressure (BP) range during antihypertensive treatment. This parameter was assessed in patients with moderate hypertension using a low-dose triple combination of antihypertensives (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) compared to usual care.

Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.

Thromboembolic disease is a common comorbidity in adult trauma patients, thus making routine thromboprophylaxis appropriate for these patients, most often in the form of low-molecular-weight heparins (LMWH). Standard thromboprophylaxis dosing regimens, however, are often associated with insufficient anti-Xa activity levels. A recently published clinical study by researchers from New York University focused on comparing the standard thromboprophylaxis regimen of enoxaparin with a weight-based dosing regimen in adult trauma patients.

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).

How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).

Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study presented below examined the efficacy and safety of an alternative treatment with ceftaroline (a 5th generation cephalosporin) for this indication.

Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past. The efficacy and safety of a fixed combination of olopatadine and mometasone in a nasal spray (GSP301) was evaluated in the study presented below by a team of American authors.

The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.

People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy can prevent these lost years.

Starting May 1st, health insurance companies will cover Jardiance^® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists, angiologists, and internists will be able to prescribe it with reimbursement. This decision was made by the State Institute for Drug Control (SÚKL) in mid-April. Hundreds of thousands of Czechs suffering from this serious condition will now have access to another effective medication. The drug is manufactured by Boehringer Ingelheim.

The relationship between the gut microbiome and multiple sclerosis has been a major topic recently. How far has current science progressed in decoding this issue? A recent review article published in the journal Neuroscience Research summarizes the existing findings on the relationship of the gut microbiome to the etiopathogenesis and course of multiple sclerosis (MS).

Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?